Jefferies Financial Group Weighs in on Kalvista Pharmaceuticals Inc’s Q1 2020 Earnings (NASDAQ:KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) – Jefferies Financial Group issued their Q1 2020 EPS estimates for shares of Kalvista Pharmaceuticals in a report released on Tuesday, July 16th. Jefferies Financial Group analyst M. Raycroft expects that the specialty pharmaceutical company will post earnings of ($0.66) per share for the quarter. Jefferies Financial Group also issued estimates for Kalvista Pharmaceuticals’ Q2 2020 earnings at ($0.73) EPS, Q3 2020 earnings at ($0.23) EPS, Q4 2020 earnings at ($0.84) EPS, FY2020 earnings at ($1.81) EPS, FY2021 earnings at ($3.47) EPS and FY2023 earnings at ($0.03) EPS.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, July 15th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.07). Kalvista Pharmaceuticals had a negative net margin of 127.20% and a negative return on equity of 24.57%. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.64 million.

KALV has been the topic of several other reports. ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Roth Capital restated a “buy” rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. Zacks Investment Research cut H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. TheStreet upgraded VEON from a “d+” rating to a “c-” rating in a research note on Thursday, July 11th. Finally, BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $29.40.

Shares of NASDAQ:KALV opened at $17.55 on Friday. The company’s fifty day moving average is $19.70. Kalvista Pharmaceuticals has a 1-year low of $7.95 and a 1-year high of $34.92. The company has a market cap of $305.19 million, a PE ratio of -12.72 and a beta of 2.12.

Several institutional investors have recently made changes to their positions in KALV. FMR LLC purchased a new stake in shares of Kalvista Pharmaceuticals during the 1st quarter valued at $21,036,000. Barclays PLC increased its holdings in Kalvista Pharmaceuticals by 88,319.7% in the 4th quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 62,707 shares during the last quarter. Marshall Wace LLP purchased a new stake in Kalvista Pharmaceuticals in the 1st quarter worth about $843,000. Laurion Capital Management LP increased its holdings in Kalvista Pharmaceuticals by 94.9% in the 1st quarter. Laurion Capital Management LP now owns 58,871 shares of the specialty pharmaceutical company’s stock worth $1,685,000 after acquiring an additional 28,670 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in Kalvista Pharmaceuticals by 133.5% in the 4th quarter. BlackRock Inc. now owns 45,078 shares of the specialty pharmaceutical company’s stock worth $891,000 after acquiring an additional 25,769 shares during the last quarter. 80.64% of the stock is owned by hedge funds and other institutional investors.

In other news, CFO Benjamin L. Palleiko sold 3,073 shares of the firm’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $25.70, for a total transaction of $78,976.10. Following the completion of the sale, the chief financial officer now directly owns 33,573 shares of the company’s stock, valued at approximately $862,826.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Albert Cha bought 61,280 shares of the firm’s stock in a transaction dated Friday, July 19th. The shares were acquired at an average cost of $17.79 per share, with a total value of $1,090,171.20. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 20,428 shares of company stock valued at $440,900. Insiders own 38.40% of the company’s stock.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: Understanding Options Trading

Earnings History and Estimates for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.